Results 251 to 260 of about 7,204,743 (394)

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon   +9 more
wiley   +1 more source

Interferon-β1a-Induced Thrombotic Microangiopathy: Possible Implication of the Alternative Pathway of the Complement. [PDF]

open access: yesKidney Int Rep, 2022
Taghavi M   +6 more
europepmc   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

open access: yesMolecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga   +2 more
wiley   +1 more source

Staphylococcus aureus can use an alternative pathway to be internalized by osteoblasts in absence of β1 integrins. [PDF]

open access: yesSci Rep
Tricou LP   +7 more
europepmc   +1 more source

#3375 The alternative pathway of the renin angiotensin aldosterone system is overactivated in severe COVID-19 at baseline [PDF]

open access: bronze
Irene Martínez Díaz   +9 more
openalex   +1 more source

... and alternative pathways [PDF]

open access: yesNature Reviews Molecular Cell Biology, 2001
openaire   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy